HTG MOLECULAR DIAGNOSTICS, INC. HTG Molecular Diagnostics, Inc. Share Price
Equities
HTGMQ
US40434H3021
Advanced Medical Equipment & Technology
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.0025 USD | +66.67% |
|
0.00% | +92.31% |
| 2023 | Motion for De Minimus Asset Sale Approved for HTG Molecular Diagnostics, Inc. | CI |
| 2023 | Motion for De Minimus Asset Sale Filed by HTG Molecular Diagnostics, Inc. | CI |
| Sales 2021 | 8.91M 713M | Sales 2022 | 6.37M 510M | Capitalization | 3.67M 294M |
|---|---|---|---|---|---|
| Net income 2021 | -17M -1.36B | Net income 2022 | -21M -1.68B | EV / Sales 2021 | 3.96 x |
| Net cash position 2021 | 5.74M 459M | Net cash position 2022 | 3.41M 273M | EV / Sales 2022 | 0.04 x |
| P/E ratio 2021 |
-2.19
x | P/E ratio 2022 |
-0.16
x | Employees | 54 |
| Yield 2021 * |
-
| Yield 2022 |
-
| Free-Float | 98% |
More Fundamentals
* Assessed data
More news
More recommendations
More press releases
| 1 day | +66.67% | ||
| Current month | +66.67% | ||
| 1 month | +66.67% | ||
| 3 months | +92.31% | ||
| 6 months | -85.71% | ||
| Current year | +92.31% |
1 week
0.00
0.00
1 month
0.000.00
Current year
0.000.01
1 year
0.003.24
3 years
0.0083.76
5 years
0.00471.60
10 years
0.003 555.01
| Managers | Title | Age | Since |
|---|---|---|---|
John Lubniewski
CEO | Chief Executive Officer | 60 | 31/03/11 |
Shaun McMeans
DFI | Director of Finance/CFO | 62 | 31/01/12 |
| Chief Administrative Officer | 45 | 31/12/14 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 66 | 26/10/15 | |
| Director/Board Member | 59 | 26/01/22 | |
Ann Hanham
CHM | Chairman | 71 | 28/08/16 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26/04/24 | 0.0025 | +66.67% | 1,835 |
| 25/04/24 | 0.0015 | -40.00% | 1,088 |
| 22/04/24 | 0.0025 | 0.00% | 933 |
| 19/04/24 | 0.0025 | +66.67% | 1,008 |
Delayed Quote OTC Markets, April 26, 2024 at 08:59 pm
More quotes
HTG Molecular Diagnostics, Inc. is a life science company. The Company is focused on advancing precision medicine and drug discovery through its transcriptome-wide profiling and advanced drug discovery platform technologies. The Company is engaged in the sales of its HTG EdgeSeq system and integrated next-generation sequencing-based (NGS-based) HTG EdgeSeq research use only (RUO) assays and from sample processing services. Its HTG EdgeSeq profiling technology measures ribonucleic acid (RNA) using deoxyribonucleic acid (DNA) nuclease protection probes (DNA protection probes). Its profiling product and service solutions enable targeted RNA profiling using a small amount of biological sample, in liquid or solid forms. Its menu of HTG EdgeSeq assays includes the HTG Transcriptome Panel (HTP), which is designed to measure approximately 20,000 mRNA targets using its HTG EdgeSeq technology, is automated on its HTG EdgeSeq system.
Calendar
08/05/2024
- Q1 2024 Earnings Release (Projected)
| 1st Jan change | Capi. | |
|---|---|---|
| +92.31% | 5.54K | |
| -12.91% | 19.08B | |
| -46.21% | 2.65B | |
| +18.15% | 1.87B | |
| -3.12% | 1.61B | |
| +23.78% | 1.21B | |
| -10.69% | 1.02B | |
| -20.89% | 905M | |
| -7.14% | 716M | |
| -18.10% | 682M |
- Stock Market
- Equities
- HTGMQ Stock
